Integrated Filing — IndAS

General information about company
Scrip Code	524470
NSE Symbol	SYNCOMF
MSEI Symbol	NOTLISTED
ISIN	INE312C01025
Name of company	SYNCOM FORMULATIONS (INDIA) LIMITED
Type of company	Main Board
Class of security	Equity
Date of start of financial year	01-Apr-2024
Date of end of financial year	31-Mar-2025
Date of board meeting when results were approved	19-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange	13-May-2025
Description of presentation currency	INR (in Actuals)
Reporting Type	Quarterly
Reporting Quarter	Fourth quarter
Nature of report standalone or consolidated	Consolidated
Whether results are audited or unaudited for the quarter ended	Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended	Audited
Segment Reporting	Multi segment
Description of single segment
Start date and time of board meeting	19-May-2025   16:00:00
End date and time of board meeting	19-May-2025   17:45:00
Whether cash flow statement is applicable on company	Yes
Type of cash flow statement	Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification	Declaration of unmodified opinion

Financial Results Ind-AS
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1	Income
	Revenue from operations	1488764000	4650126000
	Other income	69428000	174340000
	Total income	1558192000	4824466000
2	Expenses
(a)	Cost of materials consumed	801605000	2780293000
(b)	Purchases of stock-in-trade	157928000	399675000
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	44121000	-106615000
(d)	Employee benefit expense	149747000	521737000
(e)	Finance costs	1168000	8649000
(f)	Depreciation, depletion and amortisation expense	12864000	51939000
(f)	Other Expenses
1	OTHER EXPENSES	157840000	513719000
	Total other expenses	157840000	513719000
	Total expenses	1325273000	4169397000
3	Total profit before exceptional items and tax	232919000	655069000
4	Exceptional items	82000	58000
5	Total profit before tax	233001000	655127000
6	Tax expense
7	Current tax	46000000	147443000
8	Deferred tax	10058000	13338000
9	Total tax expenses	56058000	160781000
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0
11	Net Profit Loss for the period from continuing operations	176943000	494346000
12	Profit (loss) from discontinued operations before tax	0	0
13	Tax expense of discontinued operations	0	0
14	Net profit (loss) from discontinued operation after tax	0	0
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0
16	Total profit (loss) for period	176943000	494346000
17	Other comprehensive income net of taxes	-22819000	45802000
18	Total Comprehensive Income for the period	154124000	540148000
19	Total profit or loss, attributable to
	Profit or loss, attributable to owners of parent	0	0
	Total profit or loss, attributable to non-controlling interests	0	0
20	Total Comprehensive income for the period attributable to
	Comprehensive income for the period attributable to owners of parent	0	0
	Total comprehensive income for the period attributable to owners of parent non-controlling interests	0	0
21	Details of equity share capital
	Paid-up equity share capital	940000000	0
	Face value of equity share capital	1	0
27	Details of debt securities
22	Reserves excluding revaluation reserve		2459038000
23	Earnings per share
i	Earnings per equity share for continuing operations
	Basic earnings (loss) per share from continuing operations	0.16	0.57
	Diluted earnings (loss) per share from continuing operations	0.16	0.57
ii	Earnings per equity share for discontinued operations
	Basic earnings (loss) per share from discontinued operations	0	0
	Diluted earnings (loss) per share from discontinued operations	0	0
ii	Earnings per equity share
	Basic earnings (loss) per share from continuing and discontinued operations	0.16	0.57
	Diluted earnings (loss) per share from continuing and discontinued operations	0.16	0.57
24	Debt equity ratio	0	0
25	Debt service coverage ratio	0	0
26	Interest service coverage ratio	0	0
27	Disclosure of notes on financial results

Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio

Statement of Asset and Liabilities
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-Apr-2024
Date of end of reporting period		31-Mar-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Consolidated
	Assets
1	Non-current assets
	Property, plant and equipment	775261000
	Capital work-in-progress	0
	Investment property	473344000
	Goodwill	0
	Other intangible assets	472000
	Intangible assets under development	0
	Biological assets other than bearer plants	0
	Investments accounted for using equity method	0
	Non-current financial assets
	Non-current investments	36182000
	Trade receivables, non-current	0
	Loans, non-current	0
	Other non-current financial assets	139714000
	Total non-current financial assets	175896000
	Deferred tax assets (net)	0
	Other non-current assets	8158000
	Total non-current assets	1433131000
2	Current assets
	Inventories	413320000
	Current financial asset
	Current investments	892164000
	Trade receivables, current	1075485000
	Cash and cash equivalents	7120000
	Bank balance other than cash and cash equivalents	0
	Loans, current	54353000
	Other current financial assets	35322000
	Total current financial assets	2064444000
	Current tax assets (net)	0
	Other current assets	221912000
	Total current assets	2699676000
3	Non-current assets classified as held for sale	0
4	Regulatory deferral account debit balances and related deferred tax Assets	0
	Total assets	4132807000
	Equity and liabilities
1	Equity
	Equity attributable to owners of parent
	Equity share capital	940000000
	Other equity	2481576000
	Total equity attributable to owners of parent	3421576000
	Non controlling interest	0
	Total equity	3421576000
2	Liabilities
	Non-current liabilities
	Non-current financial liabilities
	Borrowings, non-current	0
	Trade payables, non-current
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	0
	Total Trade payable	0
	Other non-current financial liabilities	13335000
	Total non-current financial liabilities	13335000
	Provisions, non-current	41684000
	Deferred tax liabilities (net)	63105000
	Deferred government grants, Non-current	0
	Other non-current liabilities	0
	Total non-current liabilities	118124000
	Current liabilities
	Current financial liabilities
	Borrowings, current	45836000
	Trade payables, current
	(A) Total outstanding dues of micro enterprises and small enterprises	228133000
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	199841000
	Total Trade payable	427974000
	Other current financial liabilities	21300000
	Total current financial liabilities	495110000
	Other current liabilities	56162000
	Provisions, current	41835000
	Current tax liabilities (Net)	0
	Deferred government grants, Current	0
	Total current liabilities	593107000
3	Liabilities directly associated with assets in disposal group classified as held for sale
4	Regulatory deferral account credit balances and related deferred tax liability
	Total liabilities	711231000
	Total equity and liabilites	4132807000
	Disclosure of notes on assets and liabilities

Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars		3 months/ 6 month ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period		01-Jan-2025	01-Apr-2024
Date of end of reporting period		31-Mar-2025	31-Mar-2025
Whether accounts are audited or unaudited		Audited	Audited
Nature of report standalone or consolidated		Consolidated	Consolidated
1	Segment Revenue (Income)
	(net sale/income from each segment should be disclosed)
1	Pharmaceuticals Drugs & Formulations	1525954000	4702733000
2	Trading of Commodities	21345000	82584000
3	Renting of Property	10893000	39149000
	Total Segment Revenue	1558192000	4824466000
	Less: Inter segment revenue	0	0
	Revenue from operations	1558192000	4824466000
2	Segment Result
	Profit (+) / Loss (-) before tax and interest from each segment
1	Pharmaceuticals Drugs & Formulations	223706000	625862000
2	Trading of Commodities	419000	2035000
3	Renting of Property	10044000	35879000
	Total Profit before tax	234169000	663776000
	i. Finance cost	1168000	1168000
	ii. Other Unallocable Expenditure net off Unallocable income	0	0
	Profit before tax	233001000	655127000
3	(Segment Asset - Segment Liabilities)
	Segment Asset
1	Pharmaceuticals Drugs & Formulations	3611142000	3611142000
2	Trading of Commodities	44867000	44867000
3	Renting of Property	476798000	476798000
	Total Segment Asset	4132807000	4132807000
	Un-allocable Assets	0	0
	Net Segment Asset	4132807000	4132807000
4	Segment Liabilities
	Segment Liabilities
1	Pharmaceuticals Drugs & Formulations	688849000	688849000
2	Trading of Commodities	8276000	8276000
3	Renting of Property	14104000	14104000
	Total Segment Liabilities	711229000	711229000
	Un-allocable Liabilities	0	0
	Net Segment Liabilities	711229000	711229000
	Disclosure of notes on segments	Textual Information(2)

Text Block

Textual Information(2)

Notesttttt nThe above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 19052025ttttt nThese above results have been prepared in compliance with the Indian Accounting Standard referred to as Ind ASas notified prescribed under Section 133 of the Companies Act 2013 read with Companies Indian Accounting Standards Rules 2015 as amended from time to time. ttttt nThe company is operating in 3 segments ie Pharmaceuticals Drugs Formulations b Trading of Commodities c Renting of Property particulars of segment wise results are given as required.ttttt nThe Standalone Statement of Assets and Liabilities as at 31st March 2025 and the Standalone Statement of Cash Flow is provided as an annexure to this statement.ttttt nAs required under Regulation 33 of SEBI LODR Regulations 2015 the Auditors report provided by the Statutory Auditors have carried out Audit books of Accounts for the Financial year 2024 2025 and issued us an Audit Report with an unmodified opinion on Audited financial Results for the Quarter Year ended 31st March 2025 Therefor the company is not required to give statement of Impact of Audit Qualification for Audit report with modified opinionttttt nPrevious period figures have been regrouped/reclassified wherever necessary to confirm to this period classification ttttt nThe figures of the Last Quarter are the balancing figures between the audited figures in respect of full financial year & the published year to date figures upto 3rd quarter of that financial year nThe Company has three Wholly Owned Subsidiaries namely Synmer Pharma Private Limited, Vincit Biotech International Private Limited, Sante Biotech Private Limited

Other Comprehensive Income
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)
A	Date of start of reporting period	01-Jan-2025	01-Apr-2024
B	Date of end of reporting period	31-Mar-2025	31-Mar-2025
C	Whether results are audited or unaudited	Audited	Audited
D	Nature of report standalone or consolidated	Consolidated	Consolidated
	Other comprehensive income [Abstract]
1	Amount of items that will not be reclassified to profit and loss
	Total Amount of items that will not be reclassified to profit and loss
2	Income tax relating to items that will not be reclassified to profit or loss	0	0
3	Amount of items that will be reclassified to profit and loss
1	Items that will be reclassified to profit and loss account	-22819000	45802000
	Total Amount of items that will be reclassified to profit and loss	-22819000	45802000
4	Income tax relating to items that will be reclassified to profit or loss	0	0
5	Total Other comprehensive income	-22819000	45802000

Cash flow statement, indirect
Particulars				Year ended (dd-mm-yyyy)
A	Date of start of reporting period			2024-04-01
B	Date of end of reporting period			2025-03-31
C	Whether results are audited or unaudited			Audited
D	Nature of report standalone or consolidated			Consolidated
Part I	Blue color marked fields are non-mandatory.
	Statement of cash flows
	Cash flows from used in operating activities
	Profit before tax			655127000
	Adjustments for reconcile profit (loss)
	Adjustments for finance costs			8649000
	Adjustments for decrease (increase) in inventories			-202505000
	Adjustments for decrease (increase) in trade receivables, current			-42501000
	Adjustments for decrease (increase) in trade receivables, non-current			0
	Adjustments for decrease (increase) in other current assets			-111635000
	Adjustments for decrease (increase) in other non-current assets			0
	Adjustments for other financial assets, non-current			0
	Adjustments for other financial assets, current			-11575000
	Adjustments for other bank balances			0
	Adjustments for increase (decrease) in trade payables, current			186535000
	Adjustments for increase (decrease) in trade payables, non-current			0
	Adjustments for increase (decrease) in other current liabilities			14892000
	Adjustments for increase (decrease) in other non-current liabilities			0
	Adjustments for depreciation and amortisation expense			48025000
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss			0
	Adjustments for provisions, current			5526000
	Adjustments for provisions, non-current			0
	Adjustments for other financial liabilities, current			-62000
	Adjustments for other financial liabilities, non-current			0
	Adjustments for unrealised foreign exchange losses gains			0
	Adjustments for dividend income			0
	Adjustments for interest income			0
	Adjustments for share-based payments			0
	Adjustments for fair value losses (gains)			0
	Adjustments for undistributed profits of associates			0
	Other adjustments for which cash effects are investing or financing cash flow			0
	Other adjustments to reconcile profit (loss)			-168672000
	Other adjustments for non-cash items			0
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships			0
	Total adjustments for reconcile profit (loss)			-273323000
	Net cash flows from (used in) operations			381804000
	Dividends received			0
	Interest paid			0
	Interest received			0
	Income taxes paid (refund)			147443000
	Other inflows (outflows) of cash			0
	Net cash flows from (used in) operating activities			234361000
	Cash flows from used in investing activities
	Cash flows from losing control of subsidiaries or other businesses			0
	Cash flows used in obtaining control of subsidiaries or other businesses			0
	Other cash receipts from sales of equity or debt instruments of other entities			0
	Other cash payments to acquire equity or debt instruments of other entities			0
	Other cash receipts from sales of interests in joint ventures			0
	Other cash payments to acquire interests in joint ventures			0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships			0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships			0
	Proceeds from sales of property, plant and equipment			0
	Purchase of property, plant and equipment			99593000
	Proceeds from sales of investment property			0
	Purchase of investment property			217767000
	Proceeds from sales of intangible assets			0
	Purchase of intangible assets			0
	Proceeds from sales of intangible assets under development			0
	Purchase of intangible assets under development			0
	Proceeds from sales of goodwill			0
	Purchase of goodwill			0
	Proceeds from biological assets other than bearer plants			0
	Purchase of biological assets other than bearer plants			0
	Proceeds from government grants			0
	Proceeds from sales of other long-term assets			0
	Purchase of other long-term assets			0
	Cash advances and loans made to other parties			0
	Cash receipts from repayment of advances and loans made to other parties			0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts			0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts			0
	Dividends received			0
	Interest received			0
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			135318000
	Net cash flows from (used in) investing activities	-182042000
	Cash flows from used in financing activities
	Proceeds from changes in ownership interests in subsidiaries			0
	Payments from changes in ownership interests in subsidiaries			0
	Proceeds from issuing shares			0
	Proceeds from issuing other equity instruments			0
	Payments to acquire or redeem entity's shares			0
	Payments of other equity instruments			0
	Proceeds from exercise of stock options			0
	Proceeds from issuing debentures notes bonds etc			0
	Proceeds from borrowings			-679030000
	Repayments of borrowings			0
	Payments of lease liabilities			0
	Dividends paid			0
	Interest paid			8649000
	Income taxes paid (refund)			0
	Other inflows (outflows) of cash			8646000
	Net cash flows from (used in) financing activities			-679033000
	Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes			-626714000
	Effect of exchange rate changes on cash and cash equivalents
	Effect of exchange rate changes on cash and cash equivalents			0
	Net increase (decrease) in cash and cash equivalents			-626714000
	Cash and cash equivalents cash flow statement at beginning of period			633834000
	Cash and cash equivalents cash flow statement at end of period			7120000